Halo Therapeutics is now enrolling patients in our initial clinical trial of HT-100 for Duchenne muscular dystrophy. For more information about participating in the HT-100 clinical program, please contact us at email@example.com. For a description of our first clinical trial, please visit clinicaltrials.gov.
You can share this discussion in two ways…
Share this link:
Send it with your computer's email program: Email this